GlaxoSmithKline Pharmaceuticals Limited declared its financial results for the quarter ended September 30, 2022 by reporting 9% sales growth across the General Medicines and Specialty business. 

Revenue (from continuing operations) for the quarter came in at Rs. 906 crore whereas PAT for the period (from continuing operations) at Rs. 194 crore recorded a growth of 3%. EBITDA margins (from continuing operations) improved by 63 basis points.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, “GSK India has delivered another quarter of strong performance in general medicines and specialty business, gaining market share. We hope to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth."

"Vaccines business was impacted due to low vaccination rates, as the overall market for the self-pay segment in which we operate continues to decline. We maintain market leadership in the private vaccines market as many of our key brands gained share, fuelled by disciplined execution,” added Venkatesh.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together.